AbbVie has completed a Phase 3 trial assessing BOTOX (botulinum toxin Type A) injections for masseter muscle prominence in adults. The trial, sponsored by AbbVie, has reached completion status, supporting the company's supplemental Biologics License Application (sBLA) filed with the FDA for this cosmetic indication.
Regulatory
BOTOX Masseter Indication Moves Closer to FDA OK
AbbVie's sBLA for jawline prominence shows completed trial data.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
BOTOX would be the first neurotoxin cleared for masseter prominence if approved.
Masseter reduction via botulinum toxin is already widely practiced off-label—practitioners inject 20–50 units per side to soften jawline prominence and reduce bruxism-related hypertrophy. Formal FDA approval would make BOTOX the first and only neurotoxin cleared for this specific use, creating a significant marketing and reimbursement advantage over Dysport and Jeuveau. Approval could unlock a new patient segment seeking non-surgical jawline refinement, particularly in Asian markets where masseter prominence is a top aesthetic concern. Timeline to decision remains unclear, but completion of the trial removes a major regulatory hurdle.
Source: original report ↗
Frequently asked questions
Can you use Botox for masseter reduction and jawline slimming?
Yes, practitioners already inject 20–50 units of Botox per side off-label to soften jawline prominence and reduce masseter muscle hypertrophy. AbbVie has completed Phase 3 trial data supporting an FDA supplemental application for this cosmetic indication, which would make it the first neurotoxin formally cleared for masseter reduction.
What is the difference between Botox, Dysport, and Jeuveau for jawline treatment?
All three are botulinum toxin products used off-label for masseter reduction, but BOTOX is on track to become the first FDA-approved option for this specific indication. Formal approval would give BOTOX a significant marketing and reimbursement advantage over Dysport and Jeuveau in the masseter market.
How much Botox do you inject into the masseter muscle?
Standard off-label dosing ranges from 20–50 units per side of the masseter muscle for jawline softening and bruxism-related hypertrophy reduction. Exact dosing varies based on muscle size and desired results.
When will Botox be FDA approved for masseter reduction?
AbbVie has completed Phase 3 trial data and filed a supplemental Biologics License Application (sBLA) with the FDA, but the timeline to regulatory decision remains unclear. Completion of the trial removes a major hurdle, but no official approval date has been announced.
Is Botox masseter reduction popular in Asian markets?
Yes, masseter prominence is a top aesthetic concern in Asian markets, and formal FDA approval could unlock significant demand for non-surgical jawline refinement in these regions. This represents a major new patient segment for practices offering the treatment.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.